A Multi Center, Open Label Study of the Human Anti TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease.

Trial Profile

A Multi Center, Open Label Study of the Human Anti TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ADHERE
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Mar 2018 Results of pooled data from 11 induction, maintenance and open-label extension studies of adalimumab, were published in the Advances in Therapy.
    • 27 Jan 2018 Results assessing the safety of Adalimumab Dosed Every Week and Every Other Week in patients from this and 12 other studies, published in the American Journal of Clinical Dermatology
    • 31 Oct 2012 Planned number of patients added (960) as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top